Crucell and Talecris in protein licensing deal
This article was originally published in Scrip
Crucell is to receive up to $32.5 million for licensing its PER.6 cell line technology to Talecris Biotherapeutics.Talecris will gain an exclusive commercial licence to the technology for the development of an undisclosed and specific protein. The Dutch company will receive $2.5 million up front following the execution of the agreement and be eligible for a further $30 million in milestone payments across multiple indications. The PER.6 platform enables the large-scale manufacture of biopharmaceuticals such as recombinant proteins, including monoclonal antibodies. Talecris is being acquired by Australia'sCSL, the world's second largest manufacturer of plasma products, for $3.1 billion (ScripOnline, August 14th, 2008).
You may also be interested in...
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.